1
|
Tirado-Conte G, Panagides V, Vergara-Uzcategui CE, Veiga Fernández G, Vílchez JP, Cepas-Guillén P, Oteo JF, Barrero A, Marroquín L, Farjat-Pasos JI, Arslani K, Jiménez-Quevedo P, Núñez-Gil I, Mejía-Rentería H, de la Torre Hernández JM, Díez Gil JL, Regueiro A, Amat-Santos I, Fernández-Ortiz A, Eid-Lidt G, de Backer O, Rodés-Cabau J, Nombela-Franco L. Thrombocytopenia after transcatheter aortic valve implantation. REVISTA ESPANOLA DE CARDIOLOGIA (ENGLISH ED.) 2025; 78:347-357. [PMID: 39251129 DOI: 10.1016/j.rec.2024.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2024] [Accepted: 08/21/2024] [Indexed: 09/11/2024]
Abstract
INTRODUCTION AND OBJECTIVES Thrombocytopenia frequently occurs after transcatheter aortic valve implantation (TAVI) but its impact is poorly understood. We aimed to analyze the incidence, clinical impact, and predictors of acquired thrombocytopenia after TAVI. METHODS This retrospective multicenter registry included 3913 patients undergoing TAVI with a baseline platelet count of ≥ 100 *109/L. Acquired thrombocytopenia was defined as a decrease in baseline platelet count of ≥ 50% (early nadir ≤ 3 days and late nadir ≥ 4 days) post-TAVI. The primary endpoint was 30-day all-cause mortality and secondary endpoints were procedural safety and 2-year all-cause mortality. RESULTS The incidence of acquired thrombocytopenia was 14.8% (early nadir: 61.5%, late nadir: 38.5%). Thirty-day mortality occurred in 112 (3.0%) patients and was significantly higher in those with thrombocytopenia (8.5% vs 2.0%, adjusted OR, 2.3; 95%CI, 1.3-4.2). Procedural safety was lower and 2-year mortality was higher in patients with thrombocytopenia vs those without (52.1 vs 77.0%; P <.001, and 30.2% vs 16.8%; HR, 2.2, 95%IC, 1.3-2.7) and especially in those with late nadir thrombocytopenia (45.8% vs 54.5%; P=.056, and 38.6% vs 23.8%, HR, 2.1; 95%CI, 1.5-2.9). Independent predictors of thrombocytopenia comprised baseline and procedural factors such as body surface area, absence of diabetes, poorer renal function, peripheral vascular disease, nontransfemoral access, vascular complications, type of transcatheter heart valve, and earlier TAVI procedures. CONCLUSIONS Acquired thrombocytopenia was common (15%) after TAVI and was associated with increased short- and mid-term mortality and decreased procedural safety. Moreover, late thrombocytopenia compared with early thrombocytopenia was associated with significantly worse clinical outcomes. Further investigations are needed to elucidate the etiologic mechanisms behind these findings.
Collapse
Affiliation(s)
- Gabriela Tirado-Conte
- Instituto Cardiovascular, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
| | - Vassili Panagides
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | | | - Gabriela Veiga Fernández
- Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - Jean Paul Vílchez
- Servicio de Cardiología, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Hospital Universitario La Fe, Valencia, Spain
| | - Pedro Cepas-Guillén
- Servicio de Cardiología, Hospital Clínic Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Juan Francisco Oteo
- Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Alejandro Barrero
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Instituto de Ciencias del Corazón (ICICOR), Valladolid, Spain
| | - Luis Marroquín
- Instituto Cardiovascular, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Departamento de Cardiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Julio I Farjat-Pasos
- Departamento de Cardiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Ketina Arslani
- Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | | | - Iván Núñez-Gil
- Instituto Cardiovascular, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Cardiology Department, Hospital Universitario de Torrejón, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain
| | | | - José M de la Torre Hernández
- Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - José Luis Díez Gil
- Servicio de Cardiología, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Hospital Universitario La Fe, Valencia, Spain
| | - Ander Regueiro
- Servicio de Cardiología, Hospital Clínic Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ignacio Amat-Santos
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Instituto de Ciencias del Corazón (ICICOR), Valladolid, Spain
| | | | - Guering Eid-Lidt
- Departamento de Cardiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Ole de Backer
- Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Josep Rodés-Cabau
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Servicio de Cardiología, Hospital Clínic Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Luis Nombela-Franco
- Instituto Cardiovascular, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
| |
Collapse
|
2
|
Tirado-Conte G, Salazar CH, McInerney A, Cruz-Utrilla A, Jiménez-Quevedo P, Cobiella J, Gonzalo N, Carnero M, Núñez-Gil I, Mejía-Rentería H, Salinas P, Macaya F, Maroto LC, Vilacosta I, Fernández-Ortiz A, Escaned J, Macaya C, Nombela-Franco L. Incidence, clinical impact and predictors of thrombocytopenia after transcatheter aortic valve replacement. Int J Cardiol 2022; 352:21-26. [DOI: 10.1016/j.ijcard.2022.01.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Revised: 11/20/2021] [Accepted: 01/31/2022] [Indexed: 11/17/2022]
|
5
|
Fleerakkers J, Schepens M, Ranschaert W, Verrelst P, Graulus E. Aortic valve replacement using the Freedom SOLO stentless bioprosthesis: clinical and haemodynamic performance in 625 patients at medium-term follow-up. Eur J Cardiothorac Surg 2018; 54:1073-1080. [DOI: 10.1093/ejcts/ezy202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Accepted: 04/13/2018] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Marc Schepens
- Department of Cardiac Surgery, AZ St-Jan, Brugge, Belgium
| | | | - Paul Verrelst
- Department of Cardiac Surgery, AZ St-Jan, Brugge, Belgium
| | - Eric Graulus
- Department of Cardiac Surgery, AZ St-Jan, Brugge, Belgium
| |
Collapse
|